Vasoactive intestinal peptide as a bronchodilator in asthmatic subjects.

Morice AH, Unwin RJ, Sever PS

Peptides1 Mar 1984Cited by 12 (Europe PMC)

PMID6382197DOI10.1016/0196-9781(84)90250-xPepBankPUB-06382197

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In asthmatic volunteers, VIP infusion increased FEV1 after 15 minutes; the abstract reports p as greater than 0.02.
In plain wordsIn people with asthma, VIP infusion increased airway airflow after 15 minutes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseFEV1 change after 15 minutes
Study
n = 7
Outcome group
Respiratory function · Respiratory
Studied dose
6 pmol kg-1 min-1 · intravenous · 15 minutesAs given in this study (human).
Measurements
FEV1 increase
0.21 l
after 15 minutes VIP
FEV1 increase range
0.1 to 0.45 l
after 15 minutes VIP
Source sentences
Summary
Mean baseline FEV1 was 2.8 (+/- 0.3 S.E.) which was 81% of predicted and increased by 0.21 (range 0.1-0.45) l after 15 minutes infusion (p greater than 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (V.I.P.) caused bronchodilatation in 7 asthmatic volunteers when given intravenously at the rate of 6 pmol kg-1 min-1 for 15 minutes during a double blind study.
Report a problemFND-0638219701
02HumanNon-randomized trialSafety outcome
In asthmatic volunteers, tachycardia was observed during VIP infusion.
In plain wordsIn people with asthma, VIP infusion made the heart beat faster.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseTachycardia
Study
n = 7
Outcome group
Adverse events · Cardiovascular
Studied dose
6 pmol kg-1 min-1 · intravenous · 15 minutesAs given in this study (human).
Source sentences
Summary
Tachycardia and cutaneous flushing were also observed during the infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (V.I.P.) caused bronchodilatation in 7 asthmatic volunteers when given intravenously at the rate of 6 pmol kg-1 min-1 for 15 minutes during a double blind study.
Report a problemFND-0638219702
03HumanNon-randomized trialSafety outcome
In asthmatic volunteers, cutaneous flushing was observed during VIP infusion.
In plain wordsIn people with asthma, VIP infusion made the skin flush.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseCutaneous flushing
Study
n = 7
Outcome group
Adverse events · Whole body
Studied dose
6 pmol kg-1 min-1 · intravenous · 15 minutesAs given in this study (human).
Source sentences
Summary
Tachycardia and cutaneous flushing were also observed during the infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (V.I.P.) caused bronchodilatation in 7 asthmatic volunteers when given intravenously at the rate of 6 pmol kg-1 min-1 for 15 minutes during a double blind study.
Report a problemFND-0638219703
04HumanNon-randomized trialEfficacy outcome
In asthmatic volunteers, VIP infusion reduced the fall in FEV1 after histamine challenge compared with placebo, when the pre-infusion FEV1 was used as baseline.
In plain wordsIn people with asthma, VIP infusion reduced the airway narrowing caused by histamine compared with placebo.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseHistamine-induced fall in FEV1 (pre-infusion baseline)
Study
n = 7
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
6 pmol kg-1 min-1 · intravenous · 15 minutesAs given in this study (human).
Measurements
Mean fall in FEV1
0.26 l
VIP
Mean fall in FEV1
0.741 l
placebo
Source sentences
Summary
Subsequent induced bronchoconstriction with a predetermined dose of histamine was ameliorated at 180 seconds following challenge when compared with placebo. Mean fall in FEV1 0.26 compared with 0.741 when pre-infusion FEV1 was taken on baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (V.I.P.) caused bronchodilatation in 7 asthmatic volunteers when given intravenously at the rate of 6 pmol kg-1 min-1 for 15 minutes during a double blind study.
Report a problemFND-0638219704
05HumanNon-randomized trialEfficacy outcome
In asthmatic volunteers, VIP infusion reduced the fall in FEV1 after histamine challenge compared with placebo, when the FEV1 just before challenge was used as baseline; the abstract reports p as greater than 0.02.
In plain wordsIn people with asthma, VIP infusion reduced the airway narrowing caused by histamine compared with placebo, with unclear significance.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseHistamine-induced fall in FEV1 (pre-challenge baseline)
Study
n = 7
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
6 pmol kg-1 min-1 · intravenous · 15 minutesAs given in this study (human).
Measurements
Mean fall in FEV1
0.49 l
VIP
Mean fall in FEV1
0.75 l
placebo
Source sentences
Summary
Mean fall in FEV1 0.49 l compared with 0.75 l when the FEV1 immediately preceding challenge was used on baseline (p greater than 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (V.I.P.) caused bronchodilatation in 7 asthmatic volunteers when given intravenously at the rate of 6 pmol kg-1 min-1 for 15 minutes during a double blind study.
Report a problemFND-0638219705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.